Population Pharmacokinetic Modeling Of On-Demand And Surgical Use Of Nonacog Beta Pegol (N9-GP) And rFIXFc Based Upon The paradigm 7 Comparative Pharmacokinetic Study.

Simpson, Mindy L; Kulkarni, Roshni; Escuriola Ettingshausen, Carmen; Medom Meldgaard, Rikke; Cooper, David L; Klamroth, Robert

Simpson, Mindy L; Kulkarni, Roshni; Escuriola Ettingshausen, Carmen; Medom Meldgaard, Rikke; Cooper, David L; Klamroth, Robert.

Afiliación

Simpson ML; Pediatric Hematology/Oncology, Rush University Medical Center, Chicago, IL, USA.
Kulkarni R; Department of Pediatrics and Human Development, Michigan State University, East Lansing, MI, USA.
Escuriola Ettingshausen C; HZRM - Haemophilia Centre Rhein-Main, Frankfurt-Mörfelden, Mörfelden-Walldorf, Germany.
Medom Meldgaard R; Novo Nordisk A/S, Søborg, Denmark.
Cooper DL; Novo Nordisk Inc, Plainsboro, NJ, USA.
Klamroth R; Department for Internal Medicine, Vascular Medicine and Haemostaseology, Vivantes Klinikum, Berlin, Germany.

J Blood Med ; 10: 391-398, 2019.

Article en En | MEDLINE | ID: mdl-32009825

Palabras clave

N9-GP; paradigm 7 trial; population PK modeling; rFIXFc

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: J Blood Med Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google